BRPI0918593A2 - composição farmacêutica para uso no tratamento de infecções transmitidas sexualmente - Google Patents

composição farmacêutica para uso no tratamento de infecções transmitidas sexualmente

Info

Publication number: BRPI0918593A2
Authority: BR; Brazil
Prior art keywords: pharmaceutical composition; sexually transmitted; treatment; transmitted infections; pharmaceutically acceptable
Prior art date: 2008-09-04

Application number

BRPI0918593-3A

Other languages

English (en)

Inventor

García Salgado López Raúl

Arzola Paniagua Angélica

Pablo Senosiain Juan

Barranco Hernández Gustavo

Original Assignee

Laboratorios Senosiain S.A De C.V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-04

Filing date

2009-09-04

Publication date

2018-05-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41796784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0918593(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-04 Application filed by Laboratorios Senosiain S.A De C.V filed Critical Laboratorios Senosiain S.A De C.V

2018-05-22 Publication of BRPI0918593A2 publication Critical patent/BRPI0918593A2/pt

2018-12-11 Publication of BRPI0918593A8 publication Critical patent/BRPI0918593A8/pt

2020-11-10 Publication of BRPI0918593B1 publication Critical patent/BRPI0918593B1/pt

2021-05-25 Publication of BRPI0918593B8 publication Critical patent/BRPI0918593B8/pt

Links

208000015181 infectious disease Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title 1
HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 abstract 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 abstract 1
229960002227 clindamycin Drugs 0.000 abstract 1
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 abstract 1
229960004884 fluconazole Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
229960005053 tinidazole Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Gynecology & Obstetrics (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0918593A 2008-09-04 2009-09-04 composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas BRPI0918593B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
MX2008011321A MX2008011321A (es)	2008-09-04	2008-09-04	Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual.
MXMX/A/2008/011321		2008-09-04
PCT/IB2009/006738 WO2010026469A1 (es)	2008-09-04	2009-09-04	Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual

Publications (4)

Publication Number	Publication Date
BRPI0918593A2 true BRPI0918593A2 (pt)	2018-05-22
BRPI0918593A8 BRPI0918593A8 (pt)	2018-12-11
BRPI0918593B1 BRPI0918593B1 (pt)	2020-11-10
BRPI0918593B8 BRPI0918593B8 (pt)	2021-05-25

Family

ID=41796784

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0918593A BRPI0918593B8 (pt)	2008-09-04	2009-09-04	composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas

Country Status (13)

Country	Link
US (1)	US20110166087A1 (pt)
EP (1)	EP2329819B1 (pt)
KR (1)	KR101653424B1 (pt)
BR (1)	BRPI0918593B8 (pt)
CA (1)	CA2735926C (pt)
CO (1)	CO6321156A2 (pt)
EC (1)	ECSP11010941A (pt)
ES (1)	ES2734280T3 (pt)
HN (1)	HN2011000661A (pt)
MX (1)	MX2008011321A (pt)
PE (1)	PE20110448A1 (pt)
UY (1)	UY32091A (pt)
WO (1)	WO2010026469A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113768883A (zh) *	2021-08-25	2021-12-10	海南海神同洲制药有限公司	一种高稳定性盐酸克林霉素棕榈酸酯颗粒的制备方法
CN113768885A (zh) *	2021-09-16	2021-12-10	海南海神同洲制药有限公司	一种伏立康唑干混悬剂的制备工艺
CN114306209A (zh) *	2022-01-10	2022-04-12	江苏远恒药业有限公司	一种替硝唑栓的组合物及其制备方法与应用
CN116251067B (zh) *	2023-04-23	2024-06-07	淄博市中心医院	一种氟康唑片、制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094431B2 (en)	2000-10-12	2006-08-22	Mickey L. Peshoff	Method of healing skin wounds in mammals and a composition therefor
MXPA02007641A (es) *	2002-08-08	2004-04-02	Alparis Sa De Cv	Uso de farmaceutico de la combinacion de fluconazol-tinidazol y su composicion para la administracion oral.
US8309103B2 (en)	2004-01-22	2012-11-13	Alparis, S.A. De C.V.	Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage
EP1968544A2 (en) *	2006-01-05	2008-09-17	Drugtech Corporation	Drug delivery system for bioadhesion to a vulvovaginal surface
WO2008005783A2 (en) *	2006-06-30	2008-01-10	Drugtech Corporation	Treatment of non- infectious inflammatory vulvovaginitis with a bioadhesive clindamycin composition

2008
- 2008-09-04 MX MX2008011321A patent/MX2008011321A/es active IP Right Grant
2009
- 2009-09-04 ES ES09811170T patent/ES2734280T3/es active Active
- 2009-09-04 UY UY0001032091A patent/UY32091A/es not_active Application Discontinuation
- 2009-09-04 WO PCT/IB2009/006738 patent/WO2010026469A1/es not_active Ceased
- 2009-09-04 EP EP09811170.1A patent/EP2329819B1/en not_active Not-in-force
- 2009-09-04 US US13/062,182 patent/US20110166087A1/en not_active Abandoned
- 2009-09-04 BR BRPI0918593A patent/BRPI0918593B8/pt not_active IP Right Cessation
- 2009-09-04 KR KR1020117006146A patent/KR101653424B1/ko not_active Expired - Fee Related
- 2009-09-04 PE PE2011000439A patent/PE20110448A1/es active IP Right Grant
- 2009-09-04 CA CA2735926A patent/CA2735926C/en active Active
2011
- 2011-03-03 HN HN2011000661A patent/HN2011000661A/es unknown
- 2011-03-25 CO CO11036830A patent/CO6321156A2/es not_active Application Discontinuation
- 2011-04-01 EC EC2011010941A patent/ECSP11010941A/es unknown

Also Published As

Publication number	Publication date
ECSP11010941A (es)	2011-06-30
CO6321156A2 (es)	2011-09-20
BRPI0918593B8 (pt)	2021-05-25
PE20110448A1 (es)	2011-07-20
EP2329819B1 (en)	2019-05-01
BRPI0918593A8 (pt)	2018-12-11
ES2734280T3 (es)	2019-12-05
UY32091A (es)	2010-02-26
MX2008011321A (es)	2010-03-04
KR20110050678A (ko)	2011-05-16
KR101653424B1 (ko)	2016-09-01
WO2010026469A1 (es)	2010-03-11
EP2329819A1 (en)	2011-06-08
CA2735926C (en)	2016-09-06
US20110166087A1 (en)	2011-07-07
EP2329819A4 (en)	2011-09-14
HN2011000661A (es)	2013-09-16
BRPI0918593B1 (pt)	2020-11-10
CA2735926A1 (en)	2010-03-11

Legal Events

Date	Code	Title	Description
2018-06-05	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-06-12	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-10-15	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-10-22	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-03-24	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-08-18	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-11-10	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-06-25	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 15A ANUIDADE.
2024-10-15	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2790 DE 25-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
EA201270221A1 (ru)	2012-08-30	Лечение болезни крона с применением лаквинимода
JP2010222367A5 (pt)	2011-08-25
WO2008040534A3 (en)	2009-01-22	Non-mucoadhesive film dosage forms
WO2009109618A3 (en)	2009-12-10	1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
WO2009123776A3 (en)	2009-12-30	Antiviral drugs for treatment of arenavirus infection
BRPI0908124A2 (pt)	2015-08-04	Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
WO2011074015A3 (en)	2012-04-26	Composition of pharmaceutical product to treat sexual dysfunction
WO2007012022A3 (en)	2007-07-19	Unit dose form with ibuprofen-famotidine admixture
WO2009109616A3 (en)	2009-12-10	1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
MX2012000275A (es)	2012-02-08	Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
BRPI0512311A (pt)	2008-02-26	uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
NZ605469A (en)	2015-01-30	Nalbuphine-based formulations and uses thereof
BRPI0920605A2 (pt)	2015-12-22	composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
WO2009109654A8 (en)	2010-06-03	1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
MX2009011900A (es)	2010-01-20	Curacion de herida diabetica.
WO2008070010A3 (en)	2008-07-24	Hydroxylamine derivatives for the treatment of stroke
NZ591408A (en)	2012-12-21	Paracetamol and Calcium carbonate composition
MX341660B (es)	2016-08-29	Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2010003472A3 (de)	2010-07-01	Lutschzusammensetzung zur behandlung von entzündlichen erkrankungen des mund- und rachenraums
BRPI0918593A2 (pt)	2018-05-22	composição farmacêutica para uso no tratamento de infecções transmitidas sexualmente
WO2007145863A3 (en)	2008-05-29	Sustained release formulation of naltrexone
RU2011148355A (ru)	2013-06-10	Применение аллопуринола для ладонно-родошвенного синдрома
AR075866A1 (es)	2011-05-04	Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
WO2007023072A3 (en)	2007-05-03	Use of ambroxol for the treatment of rhinovirus infections
RU2011113733A (ru)	2012-10-20	Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах